Calibr progresses innovative ideas from the interface between academia and pharma into paradigm changing medicines through exceptional collaborations and partnerships:
Bill & Melinda Gates Foundation
The Gates Foundation provides generous grant funding to develop an “integrated drug discovery platform for diseases of the developing world within Calibr with the goal to identify innovative new therapeutics for the treatment of diseases in the developing world such as helminth infections, malaria, tuberculosis, diarrheal diseases, HIV and Ebola. In addition, the Gates Foundation has provided support to generate a best-in-class repurposing compound library to accelerate the discovery of new medicines for the world’s most urgent medical needs.
Bristol-Myers Squibb and Calibr have entered into a worldwide research collaboration and license agreement focused to develop new treatment approaches for fibrotic diseases. More information on the partnership can be found here.
California Institute for Regenerative Medicine
CIRM has provided funding to advance a novel regenerative therapy for osteoarthritis to a Ph1 clinical trial, and is supporting a collaboration with The Scripps Research Institute to progress a novel remyelination program toward the treatment of multiple sclerosis.
JJDRF has provided significant funding in order to leverage Calibr’s unique high-throughput screening and biologics platforms to pursue novel therapeutics to treat diabetes. In total, Calibr has received seven awards from the JDRF since mid-2012 that support approaches to address the unmet needs of type 1 diabetes patients ranging from novel small molecules targeting beta cells, functional insulins, and immune modulators. More information can be found here.
The execution of a strategic collaboration with Merck in early 2012 facilitated Calibr’s founding and initial growth. Merck has provided funding commitments to Calibr in excess of $56 million to support early stage discovery research, to which Merck is granted a right of first negotiation. More information about can be found here.
Mesothelioma Applied Research Foundation
The Mesothelioma Foundation is currently providing funding for the development of novel CAR-T cell therapies for the treatment of mesothelioma.
National Institutes of Health
The NIH is supporting a number of biomedical research programs in the laboratories of Calibr Principal Investigators.
In late 2015, Pfizer and Calibr entered into a strategic collaboration to advance a long-acting biotherapeutic for chronic heart failure into first-in-human studies. Under the terms of the agreement, Pfizer obtained an exclusive option to license the program after Calibr performs Phase 1 studies in healthy volunteers and heart failure patients. More information on the partnership can be found here.
Calibr received a Translation Award in 2014 to develop a novel semi-synthetic antibody-based immunotherapy to treat hormone-refractory prostate cancer. The award provides complete support to progress a novel therapeutic agent to investigational new drug status ready for a Phase 1 clinical trial. More information can be found here.
Calibr is working in collaboration with the TB Alliance to develop new drugs to treat tuberculosis, with a focus on developing new TB drugs with novel mechanisms of action that specifically target persistent and/or drug resistant stages of the disease.
There are currently no approved treatments for SMA. Drug discovery efforts are critical to move treatment beyond symptom management. Cure SMA provided critical initial funding to Calibr to develop drugs that target novel mechanisms of action to treat spinal muscular atrophy. These efforts are now supported by NIH award R01NS094721
The Lustgarten Foundation provided funding for the development of small molecule inhibitors of a pancreatic cancer-specific enzyme to manipulate cancer metabolism as a means to cure the disease. This support seeded an effort which has expanded to include a multi-institutional alliance.